Lipids in Health and Disease Clinical Biochemistry
Insulin-to-high-density lipoprotein cholesterol ratio as a simple and reliable surrogate marker of metabolic dysfunction–associated steatotic liver disease prevalence, steatosis severity, and metabolic burden: a cross-sectional comparison with established insulin resistance indices
Abstract
Background Insulin resistance (IR) plays a central role in the development of metabolic dysfunction-associated steatotic liver disease (MASLD). The insulin-to-high-density lipoprotein cholesterol (HDL-C) ratio (IHR), integrating fasting insulin and HDL-C, may serve as a simple surrogate marker of IR. This study evaluated the association of IHR with MASLD presence and severity. Its discriminative performance was compared with established IR indices. Methods This cross-sectional study analyzed 1,735 adults who underwent health screening using abdominal ultrasonography. Participants receiving antidiabetic medications were excluded to minimize medication-related effects on fasting insulin. MASLD was defined according to the 2023 multisociety criteria as ultrasonographic hepatic steatosis with at least one cardiometabolic risk factor. Participants were categorized into IHR quartiles. Associations were assessed using multivariable logistic regression and pre-specified subgroup analyses. The discriminative performance of IHR for MASLD was compared with that of HDL-C, fasting insulin, HOMA-IR, the triglyceride-to-HDL-C (TG/HDL-C) ratio, and the triglyceride-glucose (TyG) index using the area under the receiver operating characteristic curve (AUROC) and DeLong tests, with Holm adjustment for multiple comparisons. Results MASLD prevalence increased across IHR quartiles, from 13.6% to 66.8% ( P for trend < 0.001) and was higher in men than in women (48.8% vs. 32.9%). A higher IHR was independently associated with a greater severity of steatosis. In the adjusted model, the odds ratio (OR) for MASLD in the highest versus lowest IHR quartile was 4.80 (95% confidence interval [CI], 3.24–7.17). The association was generally consistent across subgroups and was more pronounced among normotensive participants ( P for interaction < 0.001). IHR demonstrated the highest discriminative ability for MASLD (AUROC, 0.759; 95% CI, 0.737–0.782) and significantly outperformed HDL-C, fasting insulin, HOMA-IR, the TyG index, and the TG/HDL-C ratio. Conclusions Higher IHR was independently associated with the presence of MASLD and greater severity of steatosis. This association remained evident among non-obese individuals and was more pronounced among normotensive individuals. IHR demonstrated favorable discriminative performance compared with that of established IR indices. These findings suggest that IHR may serve as a simple marker of IR underlying MASLD, with implications for earlier detection and prevention of metabolic disease.